Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Calithera Biosciences Q2 Sales $3.00M, Same YoY

Calithera Biosciences Q2 Sales $3.00M, Same YoY

Calithera Biosciences (NASDAQ:CALA) reported $3.00 million in sales this quarter. This is the same as the same period last year.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Calithera Biosciences (NASDAQ:CALA) reported $3.00 million in sales this quarter. This is the same as the same period last year.

JP Morgan Downgrades Huntsman to Underweight, Lowers Price Target to $25

By Benzinga Newsdesk

September 20, 12:22 PM

JP Morgan analyst Jeffrey Zekauskas downgrades Huntsman (NYSE:HUN) from Neutral to Underweight and lowers the price target from $30 to $25.

HUN

B of A Securities Upgrades SolarEdge Technologies to Buy, Raises Price Target to $367

By Benzinga Newsdesk

December 7, 7:42 AM

B of A Securities analyst Julien Dumoulin-Smith upgrades SolarEdge Technologies (NASDAQ:SEDG) from Neutral to Buy and raises the price target from $269 to $367.

SEDG

EF Hutton Initiates Coverage On G1 Therapeutics with Buy Rating, Announces Price Target of $35

By Benzinga Newsdesk

January 5, 5:39 AM

EF Hutton analyst Tony Butler initiates coverage on G1 Therapeutics (NASDAQ:GTHX) with a Buy rating and announces Price Target of $35.

GTHX

Earnings

Earnings Preview: Aethlon Medical

By Benzinga Insights

February 13, 3:01 PM

Aethlon Medical (NASDAQ:AEMD) is set to give its latest quarterly earnings report on Wednesday, 2024-02-14. Here’s what investors…

AEMD

Calithera Biosciences Q2 Sales $3.00M, Same YoY

Related Posts

JP Morgan Downgrades Huntsman to Underweight, Lowers Price Target to $25

B of A Securities Upgrades SolarEdge Technologies to Buy, Raises Price Target to $367

EF Hutton Initiates Coverage On G1 Therapeutics with Buy Rating, Announces Price Target of $35

Earnings Preview: Aethlon Medical